SCHEMBL29577413

SCHEMBL29577413

N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.66
ACE P12821 2/20 0.65
MME P08473 1/20 0.64
ALOX15 P16050 1/20 0.64
ECE1 P42892 3/20 0.61
OPRM1 P35372 1/20 0.61
OPRD1 P41143 1/20 0.61
ERAP2 Q6P179 1/20 0.61
ERAP1 Q9NZ08 1/20 0.61
LNPEP Q9UIQ6 1/20 0.61
KDM4E B2RXH2 1/20 0.60
MEN1 O00255 1/20 0.60
LMNA P02545 1/20 0.60
MPO P05164 1/20 0.60
MAPT P10636 1/20 0.60
TSHR P16473 1/20 0.60
BLM P54132 1/20 0.60
PMP22 Q01453 1/20 0.60
KMT2A Q03164 1/20 0.60
HIF1A Q16665 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30010554 0.99 LTA4H (0.65) LTA4HACEMMEALOX15KMT2A
SCHEMBL30010207 0.99 LTA4H (0.65) LTA4HACEMMEALOX15KMT2A
SCHEMBL29577205 0.99 LTA4H (0.65) LTA4HACEMMEALOX15KMT2A
SCHEMBL31619984 0.98 LTA4H (0.69) LTA4HACEMMEALOX15ECE1
SCHEMBL31477993 0.98 LTA4H (0.69) LTA4HACEMMEALOX15ECE1
SCHEMBL30557742 0.98 LTA4H (0.69) LTA4HACEMMEALOX15ECE1
SCHEMBL2182644 0.98 LTA4H (0.69) LTA4HACEMMEALOX15ECE1
SCHEMBL2182648 0.98 LTA4H (0.69) LTA4HACEMMEALOX15ECE1
SCHEMBL11873471 0.98 LTA4H (0.69) LTA4HACEMMEALOX15ECE1
SCHEMBL11873462 0.98 LTA4H (0.69) LTA4HACEMMEALOX15ECE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12622975-B2 Peptide-conjugated prodrugs BRANDEIS UNIVERSITY (US) 2026-05-12 US disclosed
EP-4587116-A2 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MarvelBiome, Inc. (US) 2025-07-23 EP disclosed
US-20240183860-A1 Chimeric ABC Transporters and Screening Methods GENENTECH, INC. (US) 2024-06-06 US disclosed
WO-2024058984-A2 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MarvelBiome, Inc. (US) 2024-03-21 WO disclosed
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-12-08 US disclosed
EP-3206704-B1 PEPTIDES HAVING ANTI-INFLAMMATORY PROPERTIES RIPTIDE BIOSCIENCE INC (US) 2022-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622975-B2 Peptide-conjugated prodrugs PEPD, PAM, VIP LTA4H 3533/4885ACE 1190/4885MME 824/4885
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS VIP, DNPEP, PEPD LTA4H 1299/4885ACE 486/4885MME 105/4885
US-20240183860-A1 Chimeric ABC Transporters and Screening Methods ABCB4, ABCE1, ABCD3 LTA4H 2361/4885ACE 3818/4885MME 1780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.